Description: p63 is a homolog of the tumor suppressor p53. It is identified in basal cells in the epithelial layers of a variety of tissues, including epidermis, cervix, urothelium, breast and prostate. p63 was detected in nuclei of the basal epithelium in normal prostate glands; however, it was not expressed in malignant tumors of the prostate. As a result, p63 has been reported as a useful marker for differentiating benign from malignant lesions in the prostate, particularly when used in combination with markers of high molecular weight cytokeratins and the prostate-specific marker AMACR (P504S). p63 has also been shown to be a sensitive marker for lung squamous cell carcinomas (SqCC), with a sensitivity of ~90%. Specificity for lung SqCC, vs. lung adenocarcinoma (LADC), is approximately 80%. In breast tissue, p63 has been identified in myoepithelial cells of normal ducts.Primary antibodies are available purified, or with a selection of fluorescent CF® Dyes and other labels. CF® Dyes offer exceptional brightness and photostability. Note: Conjugates of blue fluorescent dyes like CF®405S and CF®405M are not recommended for detecting low abundance targets, because blue dyes have lower fluorescence and can give higher non-specific background than other dye colors.
Product Origin: Animal - Mus musculus (mouse), Bos taurus (bovine)
Conjugate: CF740
Concentration: 0.1 mg/mL
Storage buffer: PBS, 0.1% rBSA, 0.05% azide
Clone: TP63/1786
Immunogen: Recombinant human p63 protein fragment (aa3-106) (exact sequence is proprietary)
Antibody Reactivity: p63
Entrez Gene ID: 8626
Z-Antibody Applications: WB (verified)
Verified AB Applications: WB (verified)
Antibody Application Notes: Higher concentration may be required for direct detection using primary antibody conjugates than for indirect detection with secondary antibody/ELISA: For coating order antibody without BSA/Western blotting 1-2 ug/mL/Optimal dilution for a specific application should be determined by user
English
Deutsch
